Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about EPIZYME, INC.
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented Du..
AQ
09/14EPIZYME : Announces Data from TAZVERIK« (Tazemetostat) Clinical Programs to be Presented D..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/10EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to ..
MT
08/10EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rati..
MT
08/10EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Than-Expected..
MT
08/09EPIZYME : and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVE..
AQ
08/09EPIZYME : Q2 Loss Widens, Revenue Rises; Company Names Grant Bogle as New CEO - Shares Dec..
MT
08/09EPIZYME : Q2 Earnings Snapshot
AQ
08/09EPIZYME : Announces CEO Succession
BU
08/09Epizyme, Inc. Announces Management Changes
CI
08/09EPIZYME : Earnings Flash (EPZM) EPIZYME Posts Q2 Revenue $13M
MT
08/09EPIZYME : Reports Second Quarter 2021 Financial Results and Provides Business Update
BU
08/09Epizyme, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/09HUTCHMED CHINA : To Develop, Commercialize Epizyme's Tazverik In Greater China
MT
08/09HUTCHMED CHINA : Secures Licensing Rights to Epizyme's Cancer Drug in Greater China
MT
08/09HUTCHMED CHINA : Epizyme Enter Development, Commercialization Deal For Cancer Drug In Chin..
MT
08/09HUTCHMED Limited and Epizyme, Inc. Announces Strategic Collaboration to Develop and Com..
CI
08/03EPIZYME : Announces Date of Second Quarter 2021 Financial Results
BU
06/29TURNING POINT THERAPEUTICS : Names New Chief Financial Officer
MT
06/28Epizyme, Inc. Announces Resignation of Paolo Tombesi as the Chief Financial Officer Eff..
CI
06/28Epizyme, Inc. Announces That Matthew E. Ros Will Serve as Principal Financial Officer, ..
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell 3000E Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell Microcap Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000E Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 2500 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell Small Cap Comp Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 2000 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell Microcap Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell 3000E Index
CI
06/24EISAI : ANTICANCER AGENT 'TAZVERIK TABLETS 200mg' APPROVED IN JAPAN FOR EZH2 GENE MUTATION..
AQ
06/16EPIZYME : Launches EZH2Now Testing Program With Quest Diagnostics
MT
06/16EPIZYME : Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refracto..
BU
05/25EPIZYME : to Participate in Jefferies Virtual Healthcare Conference
BU
05/12EPIZYME : Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessi..
BU
05/07EPIZYME : Morgan Stanley Adjusts Epizyme's Price Target to $10 From $11, Keeps Equal-Weigh..
MT
05/07EPIZYME : SVB Leerink Upgrades Epizyme to Outperform From Market Perform, Adjusts Price Ta..
MT
05/06EPIZYME : Wedbush Adjusts Epizyme's Price Target to $26 From $27, Maintains Outperform Rat..
MT
05/06EPIZYME : Q1 Earnings Snapshot
AQ
05/06EPIZYME : Earnings Flash (EPZM) EPIZYME Posts Q1 Revenue $7.6M
MT
05/06EPIZYME : Provides Business Update and Reports First Quarter 2021 Financial Results
BU
05/06Epizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
04/29EPIZYME : Announces Date of First Quarter 2021 Financial Results
BU
04/19EPIZYME : Morgan Stanley Adjusts Price Target on Epizyme to $11 From $14, Maintains Equal-..
MT
03/31EPIZYME : Credit Suisse Starts Epizyme at Outperform with $13 Price Target
MT
03/29INSIDER TRENDS : Insider Purchase Continues Epizyme Positive Trend
MT
03/09EPIZYME : Barclays Conference Presentation - March 2021
PU
03/03EPIZYME : Cowen Conference Presentation - March 2021
PU
03/02EPIZYME : Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Prioritie..
BU
03/02Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Pr..
CI
02/25EPIZYME : Morgan Stanley Downgrades Epizyme to Equal-Weight From Overweight; Price Target ..
MT
02/24EPIZYME : Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial..
AQ
02/24EPIZYME : to Host Strategic Vision Call on March 2, 2021
BU
02/23Epizyme, Inc. Provides Update on Clinical Trials
CI
02/23SECTOR UPDATE : Health Care Stocks Decline Premarket Tuesday
MT
02/23EPIZYME : Q4 Net Loss Widens, Revenue Rises; Shares Fall Pre-Bell
MT
02/23EPIZYME : 4Q Earnings Snapshot
AQ
02/23EPIZYME : Earnings Flash (EPZM) EPIZYME Reports Q4 Revenue $8.4M
MT
02/23Epizyme, Inc. Promotes Dr. Shefali Agarwal to Executive Vice President and Chief Medica..
CI
02/23Epizyme, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
CI
02/23EPIZYME : CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Qua..
BU
02/16EPIZYME : Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Partic..
BU
2020EPIZYME : Boehringer Ingelheim Scraps Collaboration Deal With Epizyme
MT
2020EPIZYME : Jefferies Downgrades Epizyme to Hold From Buy, Adjusts Price Target to $14 From ..
MT
2020EPIZYME : to Participate in Jefferies Virtual London Healthcare Conference
BU
2020EPIZYME : Barclays Adjusts Epizyme's Price Target to $18 From $33, Maintains Overweight Ra..
MT
2020EPIZYME : Morgan Stanley Adjusts Epizyme PT to $27 From $29, Maintains Overweight Rating
MT
2020EPIZYME : Reports Business Progress and Third Quarter 2020 Financial Results
AQ
2020EPIZYME : Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Mil..
AQ
2020BioPharma Credit PLC with BioPharma Credit Investments V LP Enter into an Amended and R..
CI
2020EPIZYME : Slumps 22% After Mixed Q3 Performance
MT
2020EPIZYME : 3Q Earnings Snapshot
AQ
1  2  3  4  5  6Next
Upcoming event on EPIZYME, INC.